GlassScriptPhysician profile
Bradley Walton Clark
NPI 1639431307
$151,572.53
in general payments reported to CMS, 2019-2025
19 companies · $9,779 in 2025
The $9,779 reported for 2025 was more than what 92% of Nuclear Cardiology providers received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $8,673 · 2021: $43K · 2022: $37K · 2023: $37K · 2024: $15K · 2025: $9,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $2,298 · Travel and Lodging: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,985.00 |
| Food and Beverage | $2,298.22 |
| Travel and Lodging | $1,211.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90,869.86 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $32,968.62 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $12,039.29 | 2022-2024 | |
| Lilly USA, LLC | $11,121.73 | 2020-2025 | Jardiance |
| Medtronic, INC. | $944.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $800.07 | 2019-2025 | |
| Boston Scientific Corporation | $636.71 | 2019-2025 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $498.65 | 2019-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $376.94 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $360.91 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $356.14 | 2019-2025 | Lifevest |
| Pfizer INC. | $161.92 | 2021-2025 | |
| Abiomed | $112.00 | 2019-2023 | Impella |
| Merck Sharp & Dohme LLC | $80.21 | 2021 | |
| Heartflow, INC. | $71.58 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.25 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $47.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $39.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.69 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.